We Should Have a Dream: Unlocking the Workings of the Genome in Cutaneous T-Cell Lymphomas
- 1 December 2009
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 9 (6), 409-411
- https://doi.org/10.3816/clm.2009.n.081
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- The leukemic stem cell niche: current concepts and therapeutic opportunitiesBlood, 2009
- Differentiation therapy of leukemia: 3 decades of developmentBlood, 2009
- Bexarotene blunts malignant T‐cell chemotaxis in Sezary syndrome: Reduction of chemokine receptor 4‐positive lymphocytes and decreased chemotaxis to thymus and activation‐regulated chemokineAmerican Journal of Hematology, 2007
- Applying the discovery of the Philadelphia chromosomeJCI Insight, 2007
- Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemiaNature Genetics, 2005
- Comparison of selective retinoic acid receptor– and retinoic X receptor–mediated efficacy, tolerance, and survival in cutaneous t-cell lymphomaJournal of the American Academy of Dermatology, 2004
- The importance of molecular monitoring in acute promyelocytic leukaemiaBest Practice & Research Clinical Haematology, 2003
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportBlood, 2001
- Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial ResultsJournal of Clinical Oncology, 2001
- Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone DeacetylaseJNCI Journal of the National Cancer Institute, 1998